The Cancer Epigenetics Laboratory investigates non-genetic alterations promoting cancer development, with a particular focus on chromatin-based mechanisms operating in solid cancers. Recent studies by our group have uncovered unexpected disease mechanisms, with direct implications for disease management (Torres et al., Science 2016, Loukas et al., Cancer Cell, 2023, Monserrat et al. Nature Cell Biology 2021). We have also used computational methods and AI approaches to gain insights into CRISPR-mediated genome editing (Chakrabarti et al, Molecular Cell 2019). Our research combines genomics, CRISPR-based genetics, microscopy and in vivo/ex vivo functional assays to uncover new biology through the study of altered cellular states in cancer, as well as to identify associated vulnerabilities that can be exploited to interfere with the disease.
We are looking for an enthusiastic scientist with a degree in a life science to join us and work on collaborative study aimed at identifying non-genetic determinants of drug resistance in cancer: https://transcan.eu/output-results/funded-projects/epiproper.kl
Qualifications: a Master degree in a life science discipline, with a focus on molecular and cellular biology, and at least 1 year of relevant research experience.
Competencies: Excellent spoken and written English, independent working capacity in line with career stage, excellent organizational and collaborative skills. Proficiency in molecular cloning, quantitative PCR, analysis of genomic DNA. Candidates are expected to be self-motivated researchers driven by scientific curiosity and proactive in developing their research projects.
Ph.D. training: Post-graduate applicants will have the possibility and will be encouraged to apply to the selection (September 2025) of the European School of Molecular Medicine SEMM (www.semm.it) to join our Ph.D. program in Molecular Medicine.
Salary: A competitive salary will be offered depending on experience and qualifications.
The Institute: The European Institute of Oncology (IEO) is one of the leading research institutes in Italy. The Department of Experimental Oncology (DEO) hosts ~250 scientists working in 20 independent research groups, and is equipped with state-of-the-art Technology Units. DEO is located within a scientific campus together with two other partner institutions: the FIRC Institute of Molecular Oncology (IFOM) and the Italian Institute of Technology (IIT). The IEO is one of the 13 members of the EU-LIFE alliance to promote excellence in life sciences in Europe. IEO is an equal opportunity employer committed to excellence through diversity.
Closing date: 30th October 2024
Posted on 23rd September 2024